Patients with glioma harboring BRAFV600E might benefit from MAPK pathway inhibitor target therapy, a rescue treatment that includes the use of RAF inhibitors and MEK inhibitors alone or in combination (38–41), and the results were encouraging (42). This evidence concerns the gene RAF1 and glioma.